Drug delivery to the brain in Alzheimer's disease: Consideration of the blood-brain barrier

被引:145
作者
Banks, William A. [1 ,2 ]
机构
[1] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[2] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA
关键词
Blood-brain barrier; Alzheimer's disease; Drug delivery; Cerebrospinal fluid; Biologicals; Peptides; Regulatory proteins; Transport; Transmembrane diffusion; P-glycoprotein; AMYLOID-BETA-PROTEIN; CENTRAL-NERVOUS-SYSTEM; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVATING POLYPEPTIDE PACAP; P-GLYCOPROTEIN EXPRESSION; GLUCAGON-LIKE PEPTIDES; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; MOUSE MODEL; ENDOTHELIAL-CELLS;
D O I
10.1016/j.addr.2011.12.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The successful treatment of Alzheimer's disease (AD) will require drugs that can negotiate the blood brain barrier (BBB). However, the BBB is not simply a physical barrier, but a complex interface that is in intimate communication with the rest of the central nervous system (CNS) and influenced by peripheral tissues. This review examines three aspects of the BBB in AD. First, it considers how the BBB may be contributing to the onset and progression of AD. In this regard, the BBB itself is a therapeutic target in the treatment of AD. Second, it examines how the BBB restricts drugs that might otherwise be useful in the treatment of AD and examines strategies being developed to deliver drugs to the CNS for the treatment of AD. Third, it considers how drug penetration across the AD BBB may differ from the BBB of normal aging. In this case, those differences can complicate the treatment of CNS diseases such as depression, delirium, psychoses, and pain control in the AD population. Published by Elsevier B.V.
引用
收藏
页码:629 / 639
页数:11
相关论文
共 195 条
[1]  
Abbatecola AM, 2011, CURR PHARM DESIGN, V17, P347
[2]   Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease [J].
Adessi, C ;
Frossard, MJ ;
Boissard, C ;
Fraga, S ;
Bieler, S ;
Ruckle, T ;
Vilbois, F ;
Robinson, SM ;
Mutter, M ;
Banks, WA ;
Soto, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (16) :13905-13911
[3]   ALBUMIN AND IMMUNOGLOBULIN IN PLASMA AND CEREBROSPINAL-FLUID, AND BLOOD-CEREBROSPINAL FLUID BARRIER FUNCTION IN PATIENTS WITH DEMENTIA OF ALZHEIMER TYPE AND MULTI-INFARCT DEMENTIA [J].
ALAFUZOFF, I ;
ADOLFSSON, R ;
BUCHT, G ;
WINBLAD, B .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1983, 60 (03) :465-472
[4]  
[Anonymous], PHYSL CSF BLOOD BRAI
[5]   A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo [J].
Atwal, Jasvinder K. ;
Chen, Yongmei ;
Chiu, Cecilia ;
Mortensen, Deborah L. ;
Meilandt, William J. ;
Liu, Yichin ;
Heise, Christopher E. ;
Hoyte, Kwame ;
Luk, Wilman ;
Lu, Yanmei ;
Peng, Kun ;
Wu, Ping ;
Rouge, Lionel ;
Zhang, Yingnan ;
Lazarus, Robert A. ;
Scearce-Levie, Kimberly ;
Wang, Weiru ;
Wu, Yan ;
Tessier-Lavigne, Marc ;
Watts, Ryan J. .
SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (84)
[6]  
BANKS WA, 1993, J PHARMACOL EXP THER, V267, P690
[7]   Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure [J].
Banks, WA ;
Tschöp, M ;
Robinson, SM ;
Heiman, ML .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (02) :822-827
[8]   Effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins [J].
Banks, WA ;
Pagliari, P ;
Nakaoke, R ;
Morley, JE .
PEPTIDES, 2005, 26 (02) :287-294
[9]   Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration [J].
Banks, WA ;
During, MJ ;
Niehoff, ML .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 309 (02) :469-475
[10]   Efflux of human and mouse amyloid β proteins 1-40 and 1-42 from brain:: Impairment in a mouse model of Alzheimer's disease [J].
Banks, WA ;
Robinson, SM ;
Verma, S ;
Morley, JE .
NEUROSCIENCE, 2003, 121 (02) :487-492